Former Google Executive to Lead Cancer Diagnostics Firm

Advertisement
By Reuters | Updated: 10 February 2016 17:38 IST
Grail, a healthcare firm developing a blood test for early cancer detection, named former Google X Senior Vice President Jeff Huber as its CEO Wednesday.

Huber said he wants to apply his experience building large-scale data systems to improve the gene sequencing technology used by Grail to detect cancerous material in patients who show no symptoms of the disease.

San Francisco-based Grail was formed by gene sequencing company Illumina Inc and received more than $100 million (roughly Rs. 678 crores) in Series A financing. Illumina is the majority owner. Key investors include technology giants Bill Gates, founder of Microsoft, and Jeff Bezos, founder of Amazon.com, as well as ARCH Venture Partners and Sutter Hill Ventures.

"Jeff helped Google map the world, and he'll help us map the molecular biology of the microscopic cancer DNA that might be circulating in our blood," said Grail board chair and Illumina CEO Jay Flatley.

Advertisement

Huber had more than a decade of experience building the systems that manage and analyze the data used for AdWords, Google Maps and the Google Apps suite before he joined Google X in 2013. It was at the research facility, known for developing self-driving cars and delivery drones, that Huber kicked off his next professional adventure of pairing data and life sciences.

Advertisement

The work took a deeply personal turn for Huber a few months after the change at Google when his wife, Laura, was diagnosed with Stage IV colon cancer. She died of the disease in November after what he called an "incredibly brave 18-month battle."

"I had already been ramping up on the biology and science behind this and then there was this very poignant reminder of the implications that there has to be a better way to do this," said Huber.

Advertisement

For the next three years, Huber said Grail's goal is to see the technology behind cancer detection and location improved and to begin large-scale clinical trials of its cancer-detection system.

The initial target market for testing will be individuals with a genetic predisposition to cancer, once it's cleared for widespread use. The ultimate goal is to see it used as "part of annual physical exams," Huber said.

Advertisement

© Thomson Reuters 2016

 

Get your daily dose of tech news, reviews, and insights, in under 80 characters on Gadgets 360 Turbo. Connect with fellow tech lovers on our Forum. Follow us on X, Facebook, WhatsApp, Threads and Google News for instant updates. Catch all the action on our YouTube channel.

Advertisement

Related Stories

Popular Mobile Brands
  1. Xiaomi 17 Ultra With 200-Megapixel Rear Camera Launched at This Price
  1. Xiaomi 17 Ultra Launched With Snapdragon 8 Elite Gen 5 SoC, Leica-Tuned 200-Megapixel Camera: Price, Features
  2. Astrophysicists Map Invisible Universe Using Warped Galaxies to Reveal Dark Matter
  3. Why Venus Is the Brightest Morning Star Visible From Earth
  4. Oppo Pad Air 5 Launched With 10,050mAh Battery, 12.1-Inch Display: Price, Specifications
  5. Dracula: A Love Tale Now Available For Streaming Online: What You Need to About its Plot, Cast, and More
  6. Xiaomi 17 Ultra Launching Today: Know Price, Features, Specifications and More
  7. South Korean Startup Innospace Fails on First Orbital Launch Attempt of Hanbit-Nano Rocket
  8. Failing Starlink Satellite Photographed in Orbit Before Fiery Reentry
  9. Russia Patents Rotating Space Station Concept to Generate Artificial Gravity in Orbit
  10. Interstellar Comet 3I/ATLAS Shows Wobbling Jets in Rare Sun-Facing Tail, Surprising Astronomers
Gadgets 360 is available in
Download Our Apps
Available in Hindi
© Copyright Red Pixels Ventures Limited 2025. All rights reserved.